SPECIALTY LABORATORIES
27027 Tourney Road 800•421•7110
Valencia, CA 91355 www.specialtylabs.com

Test Updates

September 30, 2008

Dear Colleague:

To serve you better, Specialty Laboratories is pleased to announce the immediate availability of a reflex confirmation for our rapid and sensitive *Chlamydia trachomatis* and *Neisseria gonorrhoeae* screening assay. With the addition of this reflex, clients need only order the single test, ***Chlamydia trachomatis / N. gonorrhoeae* rRNA PLUS [TMA] UR w/rfx Conf [7440U],** for fast confirmation of positive urine screening tests.

In order to adapt to recent changes in California State reporting for infectious disease, Specialty Laboratories will no longer refer to "Immunoblot" testing in the names of several assays, including HIV-1/HIV-2 reflex to Immunoblot & Hepatitis B Virus with Neutralization [9928] and HIV-2 IgG Antibodies Immunoblot [9926]. These tests will now be designated **HIV-1/HIV-2 reflex to Western Blot & Hepatitis B Virus with Neutralization [9928]** and **HIV-2 IgG Antibodies Western Blot [9926]**. We also hope that this will alleviate the confusion that reference to Immunoblot testing (which utilizes Western Blot methodology) has caused some clients.

As an aid to diagnosis and treatment of patients with non-urologic calculi, such as gall stones or stones from other sites, we will now offer **Stone Analysis, Non-Kidney Stones [4161]** by infrared spectrum analysis with an image and graph to determine the stone etiology. Our popular **Stone-A-Lyzer® [4160]** urolithiasis analysis will now offer nidus evaluation for a more complete result. Also, the **StoneRisk® Diagnostic Profile [5510]**, **UroRisk® Diagnostic Profile [5515]** and **StoneTrack® Diagnostic Monitoring Test [5520]** have been improved with more clinically-relevant reference ranges and clearer 24-hour urine collection instructions.

To expand physicians' ability to treat Hepatitis B, the **Hepatitis B Virus GenotypR™ [8132]** assay has been improved with the addition of analysis for antiviral therapeutics, Telbivudine (LdT) and Entecavir (ETV), along with the analysis of five polymerase codons relevant to drug resistance.

Additionally, we are pleased to inform you that this letter marks the conclusion of the integration activity related to Specialty's testing menu. We do not anticipate any further planned redirection of our assays going forward and now look forward to additional assay enhancements and offerings over the coming months.

We thank you for choosing *Specialty* and look forward to your continued support. For additional information, please visit our Web site at *www.specialtylabs.com* or contact Client Relations at 800-421-4449.

Respectfully Yours,

Christopher Lockhart, M.D.
Laboratory Director

New Tests:

7440U *Chlamydia trach./N gonorrhoeae* rRNA PLUS [TMA] UR w/rfx Conf (Available Immediately)

Component	Method	Reference Range/Units
N. gonorrhoeae **rRNA Urine**	**TMA**	**Not detected**
C. trachomatis **rRNA Urine**	**TMA**	**Not detected**

Specimen/Stability	Urine 20.0 (10.0) mL; Ambient 30 days, Refrigerated 30 days, Frozen 3 months.
Collection	Patient should not have urinated for at least one hour prior to collection. Patient should collect the first 10-20 mL of voided urine in a sterile, leak proof container. Collection of larger volume of urine may reduce test sensitivity. Female patients should not cleanse the labial area prior to providing the specimen. Urine specimens in Gen Probe Aptima Combo 2 transport tube and urine specimens that are still in the primary collection container can be transported to the lab ambient or refrigerated. Urine samples that were collected in the sterile cup container must be transferred into the APTIMA Combo 2 urine specimen transport tube within 24 hours of collection. Test within 30 days of collection. If longer storage is needed, freeze at -20 to -70C for up to 90 days after collection. Note: Larger volume specimens can result in lower sensitivity. Cleansing of labial area prior to collection for female patients can also affect the results.
Schedule	Monday-Sunday
Report	3 days
CPT Code	87801x1
Clinical Utility	The most sensitive, rapid screen for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*.
Notes	Please supply patient's birth date on Specialty's Test Requisition Form for Public Health Department reporting. Screen detected results will automatically reflex to confirmatory testing for an additional fee (87491 and/or 87591).

4161 Stone Analysis, Non-Kidney Stones (Available 11/4/08)

Component	Method	Reference Range/Units
Specimen Source		
Nidus	**IR (FTIR)**	
Component 1	**IR (FTIR)**	
Component 2	**IR (FTIR)**	
Weight	**Gravamet**	**mg**

Specimen/Stability	Dry Stone (other than kidney stones); Ambient 12 months, Refrigerated 12 months, Frozen 12 months.
Collection	Stones originating from sources not related to the kidney should be air-dried, then placed in a plastic tube or a urine collection cup. Do not use tape. Minute specimens may be placed in a gelatin capsule.
Shipment	Room Temperature
Schedule	Monday-Saturday
Report	3 - 4 days
CPT Code	82365
Clinical Utility	Stone Analysis is used to determining the analogy of stones. The results are often useful in determining the cause and treatment.
Notes	The Image and graph will follow the report.

Test Changes:

3515 Vitamin B1 (Thiamine)

Effective	October 28
Component	Vitamin B1
Reference Range	4.5 – 15.1 nmol/L (**New**)

4862W Aluminum Whole Blood

Effective	Immediately
Specimen/Stability	WB EDTA Trace Metal (Royal Blue Top) 2.0 (5.0) mL; Ambient 7 days, Refrigerated 30 days (**New**), Frozen 2 months.
Alternate Specimens	WB NaHep Trace Metal (Royal Blue Top).
Also Affected	DOS Code 4875W

5510 StoneRisk® Diagnostic Profile

Effective: October 7

Reference

Component		Reference Range/Units
Total Urine Volume		>2.00 (**New**) L/day
pH Urine		5.5-7.0 (**New**)
Calcium Urine		<250 (**New**) mg/day
Oxalate Urine		<45 (**New**) mg/day
Uric Acid Urine		<700 (**New**) mg/day
Citrate Urine		>320 (**New**) mg/day
Sodium Urine		<200 (**New**) mEq/day
Sulfate Urine		<30 (**New**) mmol/day
Phosphorus Urine		<1100 (**New**) mg/day
Magnesium Urine		>60 (**New**) mg/day
Ammonium Urine		14-62 (same) mEq/day
Potassium Urine		19-135 (same) mEq/day
Creatinine Urine	Male	800-2000 (same) mg/day
	Female	600-1800 mg/day
Calcium Oxalate		<2.00 (**New**)
Brushite		<2.00 (**New**)
Sodium Urate		<2.00 (**New**)
Struvite		<75.00 (**New**)
Uric Acid		<2.00 (**New**)

5520 StoneTrack® Diagnostic Monitoring Test

Effective: October 7th

Reference

Component		Reference Range/Units
Total Urine Volume		>2.00 **(New)** L/day
pH Urine		5.5-7.0 **(New)**
Calcium Urine		<250 **(New)** mg/day
Oxalate Urine		<45 **(New)** mg/day
Uric Acid Urine		<700 **(New)** mg/day
Citrate Urine		>320 **(New)** mg/day
Sodium Urine		<200 **(New)** mEq/day
Potassium Urine		19-135 (same) mEq/day
Creatinine Urine	Male	800-2000 (same) mg/day
	Female	600-1800 mg/day

Test Changes: (Cont'd)

5515 UroRisk® Diagnostic Profile

Effective: October 7th

Reference

Component	Reference Range/Units
Total Urine Volume	>2.00 **(New)** L/day
pH Urine	5.5-7.0 **(New)**
Calcium Urine	<250 **(New)** mg/day
Oxalate Urine	<45 **(New)** mg/day
Uric Acid Urine	<700 **(New)** mg/day
Citrate Urine	>320 **(New)** mg/day
Sodium Urine	<200 **(New)** mEq/day
Sulfate Urine	<30 **(New)** mmol/day
Phosphorus Urine	<1100 **(New)** mg/day
Magnesium Urine	>60 **(New)** mg/day
Potassium Urine	19-135 (same) mEq/day
Creatinine Urine Male	800-2000 (same) mg/day
Female	600-1800 mg/day
Calcium Oxalate	<2.00 **(New)**
Brushite	<2.00 **(New)**
Sodium Urate	<2.00 **(New)**
Uric Acid	<2.00 **(New)**

4877U Zinc 24hr Urine

Effective	Immediately
Specimen/Stability	Urine 24 hr 2.0 (1.0) mL; Ambient 5 days, Refrigerated 5 days, Frozen 14 days.
Collection Instruction	Collect urine in an acid washed plastic container. Avoid worksite collection. Send aliquot in a *Specialty* transfer tube.
Also affected	DOS Code 4877UR

8156 Hypersensitivity Pneumonitis Evaluation

Effective	Immediately
CPT Code	86609x5, 86001x8, 86606
Also affected	DOS Code 8157 (86606, 86609x4)

1751 Phosphatidylcholine IgG, IgM & IgA Autoabs

Effective	Immediately
Stability	Serum 1.0 (0.5) mL; Refrigerated 14 days, Frozen 2 months, Ambient (**Remove**)
Alternate	Plasma no longer accepted.
Also affected	DOS Code 1082, 1776, 1771, 1791, 1774, 1775

4333U Uric Acid 24 Hour Urine

Effective	Immediately
Collection	No longer necessary to adjust pH to >8 with 6 N Sodium Hydroxide (NaOH). (**Remove**).
Also affected	DOS Code 4333UR

Test Changes: (Cont'd)

5311U Potassium 24 Hour Urine

Effective	Immediately
Collection	Pour aliquot of urine from a well-mixed 24 hr collection into a clean leakproof container. Record the total volume in mL on the specimen container and Specialty's Test requisition form. Ship within 24 hours by overnight courier. No longer necessary to adjust pH to >8 with 6 N Sodium Hydroxide (NaOH). (**Remove**).

1271 Ribosomal P Protein IgG Autoantibodies

Effective	Immediately
CPT Code	83516
Also affected	DOS Code 1005, 1000, 1006, including all the reflex panels.

3521 Vitamin D, 25-Hydroxy (Calcifediol)

Effective	Immediately
Specimen/Stability	Serum 1.0 (0.4) mL; Ambient 5 days, Refrigerated 5 days, Frozen 2 months.
Alternate	Plasma Heparinized 1.0 (0.4) mL; Ambient 5 days, Refrigerated 5 days, Frozen 2 months. Plasma EDTA 1.0 (0.4) mL; Ambient 5 days, Refrigerated 5 days, Frozen 2 months.

4160 Stone-A-Lyzer®

Effective	October 28
Component	Nidus (**New**) Component 1 Component 2 Stone Weight

5510 StoneRisk® Diagnostic Profile

Effective	Immediately
Collection Instruction	Use only Quest 24-hour Urine Collection Kits specific for renal Stone formation diagnosis. Follow instruction in the kit. 1) Upon completion of 24-hour collection in the large orange collection container, tighten the cap on the container and mix contents in the container vigorously for one minute. A good mix will ensure accurate test result. 2) Carefully fill the two plastic white vials with urine collected in the large orange container. The two white vials must be filled within two to four hours of completion of 24-hour collection. Fill and cap vials one at a time. Cap both vials tightly, write patient's name on each vial and place in zip-lock bags provided (do not remove absorbent sheets). 3) Complete the patient information section. 4) Place the two plastic white vials in the white box. Do not mail large orange collection container.(**Additional Instruction**)
Note	Urine must only be collected and stored in the large orange collection container. Do not remove sponge from the orange collection container. Do not remove wool from white container. Do not collect the first urination at the beginning of 24-hour collection. During collection process store large orange container in a cool location.
Also affected	DOS Code 5515, 5520, 5530, 5525.

Test Changes: (Cont'd)

7575 Cytomegalovirus DNA DetectR™

Effective	Immediately
Specimen/Stability	Sterile Container/tube (STCON) is no longer accepted.

3138 Anti-Mullerian Hormone AssessR™

Effective	Immediately
Specimen/Stability	Serum 1.0 (0.5) mL; Refrigerated 5 days, Frozen 2 months.

1021 Complement Evaluation

Effective	October 28
Component	C3 Complement
	C4 Complement
	CH50
	Complement Factor B (**Remove**)

4872R Manganese RBC

Effective	Immediately
Specimen/Stability	Whole Blood EDTA Trace Metal 2.0 (0.5) mL; Ambient 72 hours (**ADD**) Refrigerated 72 hours.
Alternate	Whole Blood NaHep Trace Metal 2.0 (0.5) mL; Ambient 72hours (**ADD**) Refrigerated 72 hours.

Test Changes: (Cont'd)

8132 Hepatitis B Virus GenotypR™

Effective	October 28	
Component	Telbivudine (LdT)	(**ADD**)
	Entecavir (ETV)	(**ADD**)
	Polymerase Codon 184	(**ADD**)
	Polymerase Codon 194	(**ADD**)
	Polymerase Codon 202	(**ADD**)
	Polymerase Codon 233	(**ADD**)
	Polymerase Codon 250	(**ADD**)

Clinical Utility

Antiviral therapy available for chronic Hepatitis B includes interferon-alpha, pegylated interferon alpha-2 and several nucleoside/nucleotide analogs (NAs): Lamivudine (3TC), Adefovir (ADV), Entecavir (ETV), Telbivudine (LdT), and Tenofovir (TDF). The main application of antiviral therapy is to reach sustained suppression of HBV replication and, as a result, prevent progression of the disease.

The beneficial effect of NA therapy on suppression of HBV viral replication can be complicated by the development of mutations in the HBV polymerase gene that confer drug resistance. The incidence of drug resistance depends on several factors including: the specific drug used, baseline viral load, duration of treatment, and prior exposure to NA therapy. The patterns of drug resistant mutations associated with certain NAs were described in many studies and summarized in Practical Guidelines recommendations from the American Association for the Study of Liver Diseases. (A.Lok 2007).

Detection of the mutation M204V/I in the YMDD motif of HBV polymerase gene alone or in combination with compensatory mutation in codons 80, 173, 180 is associated with resistance to Lamivudine (3TC). This primary Lamivudine mutation (M204V/I) is cross resistant for Telbivudine (LdT). Two mutations: N236T and A 181T/V are associated with resistance to Adefovir (ADV). The substitution A181T/V is also associated with reduced susceptibility to 3TC. (Yatsuji H. et.al 2006). Any of the following HBV polymerase gene mutations T184S/C/G/A/I/L/F/M, S202G/C/I, M250V/I/L when detected in combination with lamivudine-associated mutations, result in reduced susceptibility to Entecavir (ETV) (Tenney DJ.2004).

Summary data on the HBV mutations associated with resistance to nucleoside/nucleotide analogs are provided in the table below.

Drug	Mutation associated with Resistance to NAs
Lamivudine (3TC)	M204V/I*
	A181T/V
Telbivudine (LdT)	M204I
	L180M+204V
Entecavir (ETV)	any of 184S/C/G/A/I/L/F/M
	S202G/C/I, M250M/L/I**

*Alone or in combination with any mutations in codons:80,173 and 180

**When detected with lamivudine-associated mutation (M204V/I+ L180M)

Notes

References: Lok ASF and McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45; 2: 507-39. Lok ASF, Zouilim F, Locarnini S. et.al. Antiviral drug resistance HBV : standardization of nomenclature and assay and recommendations for management. Hepatology 2007; 46:254-65. Lai CL, Dienstag J, Schiff E. et.al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patient with chronic hepatitis B. Clin.inf.Dis. 2003;36 :687-9. Hyatsuji, Noguchi C, Hiraga N. et.al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with substitution outside the YMDD motif. Antimicrobial Agent and Chemotherapy;2006;50;3867-74.

Tenney DJ., Levine SM, Rose et.al. Clinical mergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrobial Agent and Chemotherapy ; 200448: 3498-3507. Locarnini S. Primary resistance, multidrug resistance, and cross- resistance pathway in HBV as a consequence of treatment failure. Hepatol. Int. 2008;2:147-51.

Test Changes: (Cont'd)

9620 NMP22® Bladder Tumor Marker

Effective	Immediately
Name	Nuclear Matrix Proteins (NMP)
Specimen/Stability	Urine Additive 10.0 (5.0) mL; Refrigerated 7 days. Frozen 56 days.
CPT Code	86316
Collection	Collect a single void of urine between midnight and noon. Stabilize sample immediately. Stabilized urine collected with the NMP22 Urine Collection Kit should be blue/green in color. Keep sample away from direct sunlight. Transport temperature; Refrigerated.
Clinical Utility	NMP22 is involved in DNA replication. NMP22 is increased in patients with bladder carcinomas. NMP22 appears to be more sensitive and specific for low grade bladder cancers than urine cytology alone.
Note	NMP22, urine test for bladder cancer, is now approved for use as an aid in diagnosing patients at high risk for bladder cancer. The following table summarizes the diagnostic sensitivity of the NMP22 test compared to cytology, in patients with various stages and types of bladder cancer.

Test sensitivity of NMP22 Versus Bladder Cytology

Tumor Size(mm)	NMP22(%)	Bladder Wash Cytology (%)
<=10	76	32
11-20	67	37
21-30	75	36
>=31	93	85

Tumor Grade		
1	73	8
2	72	43
3	81	77

Tumor	Stage	
Ta	69	23
T1	81	64
T2 or greater	91	73

Adapted from:
Boman H, Hedelin H, Jacobsson S Holmang S. Newly Diagnosed Bladder Cancer: The Relationship of intial Symptoms, Degree of Microhematuria and Tumor Marker Status. J Urol 168: 1955-1959, 2002.

This test is performed on the Matritech NMP-22 Test Kit, which is an enzyme immunoassay (EIA) for the in vitro quantitative determination of the nuclear matrix protein NMP22 in stabilized voided urine. Values obtained with different assay methods or kits cannot be used inter-changeably. The NMP22 result should not be interpreted as evidence of the presence or absence of malignant disease in the urinary tract without corroboration from other diagnostic procedures and should only be used in conjunction with other diagnostic information in the management of patients with transitional cell carcinoma of the urinary tract.

Discontinued Tests:

Effective Immediately:

I201 **Allergen – Horse Bot Fly IgE**
Replaced by: No replacement

RC7 **Allergen – Cefaclor IgE**
Replaced by: No replacement

3143C **Beta-2-Microglobulin CSF**
Replaced by: No replacement

3258C **Carcinoembryonic Antigen CSF**
Replaced by: No replacement

3546F **PSA (Prostate-Specific Antigen) Fluid**
Replaced by: No replacement

1600F **Complement Functional Activity: Total CH50 Fluid**
Replaced by: No replacement

Effective November 4, 2008:

1650 **Cellular Immune Dysfunction Evaluation**
Replaced by: No replacement

1651 **Chronic Fatigue & Immune Dysfunction Syndrome Evaluation**
Replaced by: No replacement

5841 **Urovysion™ (FISH for Bladder Cancer)**
Replaced by: S51769 – FISH, Vysis® Urovysion™, Bladder Cancer [10107N]

Discontinued Tests: (Cont'd)

Effective November 11, 2008:

8148 **BK (Polyomavirus) DNA DetectR™**
Replaced by: S51747 – BK Virus DNA Qualitative Real-Time PCR [48900]

8149 **BK (Polyomavirus) UltraQuant®**
Replaced by: S51498 - BK Virus DNA, Quant [47900]

7920 ***Bordetella pertussis/parapertussis* DNA DetectR™**
Replaced by: S51743 - *Bordetella pertussis/parapertussis* DNA, Qual R-T PCR [45400]

7570 ***Borrelia burgdorferi* DNA DetectR™**
Replaced by: S51646 - Lyme Disease DNA, R-T PCR, CSF/Synovial Fluid [42400]

7570T ***Borrelia burgdorferi* DNA DetectR™ (Tick Only)**
Replaced by: S51737 – Lyme Disease DNA, Qualitative Real-Time PCR, Tick [42200]

3952 **Chromogranin A**
Replaced by: S51768 - Chromogranin A [34468X]

3951 **Chromogranin A, End-Point Titer**
Replaced by: S51768 – Chromogranin A [34468X]

1605 **Complement**
Replaced by: S51758 – Complement Component C2 [44842P]

1995 **Complement C4 Binding Protein**
Replaced by: S49917 - C4 Binding Protein [11335X]

1610 **Complement C5**
Replaced by: S51759 - Complement Component C5 [45054P]

1976 **Complement C6**
Replaced by: S51761 – Complement Component C6 [45070P]

1978 **Complement C7**
Replaced by: S51762 – Complement Component C7 [45088P]

1980 **Complement C8**
Replaced by: S51763 - Complement Component C8 [45096P]

Discontinued Tests: (Cont'd)

1982 **Complement C9**
Replaced by: S51764 – Complement Component C9 [45104P]

1020 **Complement Evaluation**
Replaced by: 1500 Complement C3 & C4 and S – Properdin Factor B (C3 Proactivator) [46706P]

1511 **Complement Factor B**
Replaced by: S51770 – Properdin Factor B (C3 Proactivator) [46706P]

1984 **Complement Factor H**
Replaced by: S48699 - Complement Protein Concentration Factor H

2650 **Enterovirus DetectR™**
Replaced by: S51731 – Enterovirus RNA, Qualitative Real-Time PCR [47300]

7583 **Epstein-Barr Virus DNA DetectR™**
Replaced by: S49990 - Epstein-Barr Virus DNA (PCR) [47510]

7584 **Epstein-Barr Virus DNA UltraQuant®**
Replaced by: S51739 - Epstein-Barr Virus DNA, Quantitative Real-Time PCR

7584C **Epstein-Barr Virus DNA UltraRapid® CSF**
Replaced by: S51739 - Epstein-Barr Virus DNA, Quantitative Real-Time PCR

7584P **Epstein-Barr Virus DNA UltraQuant® Plasma**
Replaced by: S51739 - Epstein-Barr Virus DNA, Quantitative Real-Time PCR

1450 **Fecal Lactoferrin**
Replaced by: S51757 – Lactoferrin, Stool [10156X]

8145 **JC Virus DNA DetectR™**
Replaced by: S51744 – JC Polyoma Virus DNA, Qualitative Real-Time PCR [41336]

8147 **JC Virus UltraQuant®**
Replaced by: S51745 – JC Polyoma Virus DNA, Quantitative Real-Time PCR [41446]

8147C **JC Virus DNA UltraRapid®**
Replaced by: S51745 – JC Polyoma Virus DNA, Quantitative Real-Time PCR [41446]

Discontinued Tests: (Cont'd)

2772 **Meningoencephalomyelitis (MEM) Panel**
Replace by: No replacement

2773C **Meningoencephalomyelitis (MEM) Summer/Fall Panel (CSF)**
Replaced by: S51732 - Meningoencephalomyelitis (MEM) Summer/Fall Panel (CSF)

2774C **Meningoencephalomyelitis (MEM) Winter Panel (CSF)**
Replaced by: S51733 - Meningoencephalomyelitis (MEM) Winter Panel (CSF)

3317 **Metanephrines, Plasma Free**
Replaced by: S51767 – Metanephrines, Fractionated, LC/MS/MS, Plasma [19548X]

2924 ***Mycoplasma pneumoniae* DNA DetectR™**
Replaced by: S51734 – *Mycoplasma pneumoniae* DNA, Qualitative Real-Time PCR [46300]

2929 ***Mycoplasma spp. (hominis, incognitus, penetrans)* DNA DetectR™**
No replacement

8261 **Parvovirus B19 Evaluation**
Replaced by: 8221 Parvovirus B19 IgG & IgM ABS and S49972 - Parvovirus (B19) DNA [43010]

8266 **Parvovirus B19 DNA DetectR™**
Replaced by: S49972 – Parvovirus (B19) DNA [43010]

8260 **Parvovirus B19 DNA UltraQuant®**
Replaced by: S51752 – Parvovirus B19 DNA, Quantitative Real-Time PCR [43100]

7585 **Varicella-Zoster Virus DNA DetectR™**
Replaced by: S51742 – Varicella-Zoster Virus (VZV) DNA, Qual Real-Time PCR [45020]

8760 **Varicella-Zoster Virus DNA UltraQuant®**
Replaced by: S51753 – Varicella-Zoster Virus (VZV) DNA, Quant Real-Time PCR [45200]

8760C **Varicella-Zoster Virus DNA UltraQuant® CSF**
Replaced by: S51753 – Varicella-Zoster Virus (VZV) DNA, Quant Real-Time PCR [45200]

8160 **West Nile Virus RNA DetectR™**
Replaced by: S51749 – West Nile Virus RNA, Qualitative Real-Time PCR [45315]

8160C **West Nile Virus RNA DetectR™ CSF**
Replaced by: S51749 – West Nile Virus RNA, Qualitative Real-Time PCR [45315]